Sysmex Corporation (TYO:6869)

Market Cap	893.07B -49.0%
Revenue (ttm)	502.95B +0.2%
Net Income	44.75B -22.6%
EPS	71.77 -22.5%
Shares Out	621.48M
PE Ratio	20.02
Forward PE	19.18
Dividend	36.00 (2.51%)
Ex-Dividend Date	Mar 30, 2026

Volume	3,370,000
Average Volume	3,164,170
Open	1,420.50
Previous Close	1,428.50
Day's Range	1,419.00 - 1,447.00
52-Week Range	1,268.00 - 2,734.00
Beta	0.65
RSI	54.02
Earnings Date	May 14, 2026

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematology analyzer ProCyte Dx for Research applications, a housed in a compact body that simultaneously measures five types of leukocytes and reticulocyte co...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1968
• Employees: 10,533
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 6869

Financial Performance

In fiscal year 2025, Sysmex's revenue was 508.64 billion, an increase of 10.21% compared to the previous year's 461.51 billion. Earnings were 53.67 billion, an increase of 8.12%.